Dr. Gronchi Alessandro
Doctor
Contacts
- Mail: alessandro.gronchi@istitutotumori.mi.it
- Mail: Chirurgia.Sarcomi@istitutotumori.mi.it
- Tel: 0223903234
Specialty / Department
- Surgery
Alessandro Gronchi MD received his MD degree from Milan University in 1992, completed his residency training in General Surgery in 1997 and a fellowship in Surgical Oncology in 1998. He holds the National Scientific qualification for full professor of General Surgery. He is chief of the Sarcoma Service since 2001 and chair of the department of Surgery since 2022 at the National Cancer Institute – Milan – Italy.
He is involved in all institutional research activities on sarcoma, which include prognostic models for soft tissue sarcomas (STS) and desmoid tumor (DT), neoadjuvant therapies in extremity and retroperitoneal sarcomas, new targets for specific STS types, genomic characterization of DF and its impact in tumor progression, mechanisms of resistance to therapy in GIST. He is the Principal Investigator of several Italian and International trials on STS, DF and GIST.
He serves as member of the board of directors of the Italian Sarcoma Group and of the Sarcoma Task Force of the European Society for Medical Oncology. He was member of the board of directors of the European Society of Surgical Oncology 2020-2024; international representative on the executive council of the SSO 2021-2024; chair of the EORTC Soft Tissue and Bone Sarcoma Group (2015-2017), president of the Connective Tissue Oncology Society (2016); president of the Italian Society of Surgical Oncology (2019-2021). He is member of the European Surgical Association, the American Society of Clinical Oncology and honorary member of the Polish Society of Surgical Oncology. He is one of the initiators of a global collaborative effort on retroperitoneal sarcoma (Trans-atlantic Australasian RetroPeritoneal Sarcoma Working Group, TARPSWG), which involves over 200 institutions worldwide.
Dr. Gronchi has authored more than 540 scientific publications (Scopus HIndex 105), serves as Associate Editor of Annals of Surgical Oncology, Journal of Surgical Oncology, ESMO Reare Cancers, Critical Reviews in Oncology/Hematology, Therapeutics Advances in Medical Oncology; Updates in Surgery.
- Mail: alessandro.gronchi@istitutotumori.mi.it
- Mail: Chirurgia.Sarcomi@istitutotumori.mi.it
- Tel: 0223903234
Chirurgia Generale 7 – Sarcomi
Collegio di Direzione
Dipartimento chirurgia oncologica
Dipartimento chirurgia oncologica
Chirurgia Generale 7 – Sarcomi
Studio randomizzato di fase III sulla chemioterapia neoadiuvante seguita da intervento chirurgico rispetto al solo intervento chirurgico per i pazienti con Sarcoma del retroperitoneo ad alto rischio (STRASS 2)
Studio prospettico di fase I-II, multicentrico, in aperto che esplora la combinazione di trabectedina in associazione a radioterapia in pazienti con sarcoma dei tessuti molli- (Studio TRASTS).
Studio prospettico di fase I-II, multicentrico, in aperto che esplora la combinazione di trabectedina in associazione a radioterapia in pazienti con sarcoma dei tessuti molli- (Studio TRASTS).
Studio randomizzato di fase III sulla chemioterapia neoadiuvante seguita da intervento chirurgico rispetto al solo intervento chirurgico per i pazienti con Sarcoma del retroperitoneo ad alto rischio (STRASS 2)
Last update: 09/09/2025